Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT: Adjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab in Stage I HR+, HER2+ Breast Cancer
NCT04569747Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2021
- Primary completion
- Mar 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Jan 2021; status: active, not recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04569747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569747.